In a mouse model, changes of CKD‐MBD including ROD were ameliorated after the administration of DKK1‐ab (in combination with phosphate binder therapy).174 In patients with multiple myeloma, administration of DKK1‐ab reduced bone resorption and reduced bone formation.34 Finally, the dual inhibition of sclerostin and DKK‐1 leads to synergistic bone formation in rodents and non‐human primates.175 These studies have important implications for patients with kidney disease, and clinical studies of DKK1‐ab are needed in CKD and ESKD cohorts. Here, DKK1 is linked to kidney disorder.